Ayer DW, et al. - In this phase 2b double-blind, randomized, placebo-controlled study of adults with migraine treated with galcanezumab (an investigational humanized antibody binding calcitonin gene-related peptide) or placebo, researchers evaluated two disease-specific patient-reported outcome (PRO) measures (The Migraine-Specific Quality of Life Questionnaire [MSQ] v2.1 and the Headache Impact Test [HIT-6]) in determining 12-week changes from baseline. MSQ scores suggest that treatment with galcanezumab was associated with significant functional improvements in comparison with placebo. Improvements in MSQ and reductions in HIT-6 scores were noted in relation to change in migraine headache days. This suggests the clinical significance of these changes in relation to PROs that measure function.